{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "38134880",
  "DateCompleted": {
    "Year": "2023",
    "Month": "12",
    "Day": "25"
  },
  "DateRevised": {
    "Year": "2024",
    "Month": "01",
    "Day": "03"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.chembiol.2023.11.014",
      "S2451-9456(23)00428-2"
    ],
    "Journal": {
      "ISSN": "2451-9448",
      "JournalIssue": {
        "Volume": "30",
        "Issue": "12",
        "PubDate": {
          "Year": "2023",
          "Month": "Dec",
          "Day": "21"
        }
      },
      "Title": "Cell chemical biology",
      "ISOAbbreviation": "Cell Chem Biol"
    },
    "ArticleTitle": "Knocking off cancer's HAT: CSS1477 disrupts oncogenic programs.",
    "Pagination": {
      "StartPage": "1505",
      "EndPage": "1507",
      "MedlinePgn": "1505-1507"
    },
    "Abstract": {
      "AbstractText": [
        "EP300/CBP are histone acetyltransferases recruited onto chromatin by oncogenic transcription factors and control the transcriptional program via their activity in enhancer areas. In the December issue of Cancer Cell, Nicosia et\u00a0al.<sup>1</sup> offer new promise in targeting EP300/CBP using the small-molecule inhibitor CSS1477 in patients with blood tumors and no other therapeutic options."
      ],
      "CopyrightInformation": "Copyright \u00a9 2023 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium; Bioscience, Oncology R&D, AstraZeneca, Waltham, MA, USA."
          }
        ],
        "LastName": "Xu",
        "ForeName": "Luyao Kevin",
        "Initials": "LK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Center for Medical Genetics, Ghent University and University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium. Electronic address: pntziachr@gmail.com."
          }
        ],
        "LastName": "Ntziachristos",
        "ForeName": "Panagiotis",
        "Initials": "P"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cell Chem Biol",
    "NlmUniqueID": "101676030",
    "ISSNLinking": "2451-9448"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "EC 2.3.1.48",
      "NameOfSubstance": "CREB-Binding Protein"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Transcription Factors"
    },
    {
      "RegistryNumber": "EC 2.3.1.48",
      "NameOfSubstance": "Histone Acetyltransferases"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Chromatin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "CREB-Binding Protein"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Transcription Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Histone Acetyltransferases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chromatin"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Neoplasms"
    }
  ],
  "CoiStatement": "Declaration of interests L.K.X. is an employee of AstraZeneca."
}